Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK2 V617F |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK2 Inhibitor JAK2 Inhibitor - ATP competitive |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04557956 | Phase Ib/II | Tazemetostat Dabrafenib + Tazemetostat + Trametinib | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Recruiting | USA | 0 |
NCT05890352 | Phase II | Lenalidomide + Tafasitamab-cxix Lenalidomide + Tafasitamab-cxix + Tazemetostat Lenalidomide + Tafasitamab-cxix + Zanubrutinib | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Recruiting | USA | 0 |
NCT02689336 | Phase II | Erlotinib + Temozolomide | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | Withdrawn | 0 | |
NCT04517851 | Phase I | Elotuzumab | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | Active, not recruiting | USA | 0 |
NCT04678336 | Phase I | CART123 cells Cyclophosphamide + Fludarabine | CD123 Redirected T Cells for AML in Pediatric Subjects | Recruiting | USA | 0 |
NCT03854474 | Phase Ib/II | Pembrolizumab + Tazemetostat | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | Active, not recruiting | USA | CAN | 0 |
NCT06093672 | Phase III | Givinostat Hydroxyurea | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera (GIV-IN PV) | Recruiting | USA | POL | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | BGR | AUT | 1 |
NCT04116502 | Phase III | Ruxolitinib Hydroxyurea Alpha 2 Interferon | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE) | Recruiting | GBR | 0 |
NCT06313593 | Phase I | INCB160058 | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT04644211 | Phase II | Ruxolitinib | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Recruiting | USA | 0 |